發(fā)布時(shí)間：2018-07-12 16:23

  本文選題：股權(quán)激勵(lì)計(jì)劃 + 激勵(lì)機(jī)制�。� 參考：《哈爾濱工業(yè)大學(xué)》2017年碩士論文

【摘要】：股權(quán)激勵(lì)計(jì)劃作為一種長(zhǎng)期有效的激勵(lì)方式,能有效地增加公司管理層的經(jīng)營(yíng)動(dòng)力,進(jìn)而服務(wù)于股東投資目標(biāo),已被西方廣泛的應(yīng)用于公司實(shí)踐并取得不錯(cuò)效果。但是,在我國(guó)這方面的理論研究和實(shí)踐發(fā)展的并不理想。R醫(yī)藥公司是A藥集團(tuán)旗下的醫(yī)藥商業(yè)平臺(tái),總部位于黑龍江省哈爾濱市,公司的主營(yíng)業(yè)務(wù)主要由醫(yī)藥批發(fā)業(yè)務(wù)及醫(yī)藥零售業(yè)務(wù)構(gòu)成,是黑龍江省藥品流通行業(yè)龍頭企業(yè),但是R醫(yī)藥公司現(xiàn)有的激勵(lì)機(jī)制中存在著一些問(wèn)題,并且由于這些問(wèn)題導(dǎo)致R醫(yī)藥公司面臨股東權(quán)益受損、優(yōu)秀人才缺失的風(fēng)險(xiǎn)。為了應(yīng)對(duì)這種風(fēng)險(xiǎn),適應(yīng)經(jīng)濟(jì)環(huán)境及公司的需求,本文希望通過(guò)對(duì)R醫(yī)藥公司的激勵(lì)機(jī)制進(jìn)行設(shè)計(jì)改善,為公司引進(jìn)股權(quán)激勵(lì)計(jì)劃這種激勵(lì)方式,為公司未來(lái)發(fā)展吸引并留住更多的“生力軍”,使公司長(zhǎng)遠(yuǎn)可持續(xù)地發(fā)展下去。本文參考了國(guó)內(nèi)外學(xué)者相關(guān)研究成果,并且對(duì)R醫(yī)藥公司的經(jīng)營(yíng)概況和所處省市經(jīng)濟(jì)情況及行業(yè)情況特點(diǎn)進(jìn)行了簡(jiǎn)明扼要的了解,對(duì)R醫(yī)藥公司的激勵(lì)機(jī)制進(jìn)行深入分析研究,之后對(duì)R醫(yī)藥公司的當(dāng)前激勵(lì)機(jī)制體系中存在的不足及問(wèn)題做了梳理和更深入的分析,發(fā)現(xiàn)R醫(yī)藥公司存在著管理層過(guò)度規(guī)避風(fēng)險(xiǎn)損害股東利益、激勵(lì)效果低、精神激勵(lì)不足、績(jī)效考核指標(biāo)設(shè)計(jì)不完善等問(wèn)題,在充分了解研究R醫(yī)藥公司的當(dāng)前內(nèi)外部環(huán)境的基礎(chǔ)上,提出對(duì)R醫(yī)藥公司實(shí)施股權(quán)激勵(lì)計(jì)劃并為其設(shè)計(jì),本文主要對(duì)股權(quán)激勵(lì)計(jì)劃的具體內(nèi)容進(jìn)行設(shè)計(jì),分別從股權(quán)激勵(lì)的模式、股票來(lái)源、授予價(jià)格、授予對(duì)象、時(shí)限安排、激勵(lì)額度、考核指標(biāo)七個(gè)方面進(jìn)行科學(xué)合理地設(shè)計(jì),結(jié)合2014-2015年已經(jīng)發(fā)布的股權(quán)激勵(lì)計(jì)劃與R醫(yī)藥公司的實(shí)際情況,主要對(duì)股權(quán)激勵(lì)計(jì)劃的行權(quán)指標(biāo)選取、指標(biāo)標(biāo)準(zhǔn)的確定進(jìn)行研究,致力于使R醫(yī)藥公司股權(quán)激勵(lì)計(jì)劃達(dá)到最優(yōu)狀態(tài)。最后,對(duì)于股權(quán)激勵(lì)計(jì)劃實(shí)施過(guò)程中可能遇到的障礙提出合理可行的建議。
[Abstract]:As a long-term and effective incentive scheme, equity incentive plan can effectively increase the management power of the company and serve the shareholders' investment target. It has been widely used in western companies and achieved good results. However, the development of theoretical research and practice in this area in China is not ideal. R Pharmaceutical Company is the pharmaceutical business platform of A Pharmaceutical Group, which is headquartered in Harbin City, Heilongjiang Province. The company's main business is mainly composed of pharmaceutical wholesale business and pharmaceutical retail business. It is a leading enterprise in the pharmaceutical circulation industry in Heilongjiang Province. However, there are some problems in the existing incentive mechanism of R Pharmaceutical Company. And as a result of these problems, R Pharmaceutical Company is faced with the risk of losing shareholders' rights and talents. In order to deal with this risk and adapt to the economic environment and the needs of the company, this paper hopes to design and improve the incentive mechanism of R Pharmaceutical Company to introduce the equity incentive plan for the company. To attract and retain more fresh forces for the future development of the company, so that the company can continue to develop in the long run. This article has consulted the domestic and foreign scholars' related research results, and has carried on the concise understanding to the R medicine company's management general situation, the province economic situation and the profession situation characteristic, has carried on the thorough analysis to the R medicine company's incentive mechanism. After that, the author combs and analyzes the problems in the current incentive mechanism system of R Pharmaceutical Company, and finds that the management of R Pharmaceutical Company has the advantages of excessive avoiding risk, harming shareholders' interests, low incentive effect and insufficient spiritual incentive. On the basis of fully understanding the current internal and external environment of R pharmaceutical company, this paper puts forward the equity incentive plan for R pharmaceutical company and designs it. This paper mainly designs the specific contents of the equity incentive plan, respectively from seven aspects of equity incentive mode, stock source, award price, granting object, time limit arrangement, incentive quota, assessment index, scientific and reasonable design. Combined with the actual situation of R Pharmaceutical Company and the stock incentive plan published in 2014-2015, this paper mainly studies the selection of the exercise index and the determination of the index standard of the equity incentive plan. Committed to R Pharmaceutical Company equity incentive plan to achieve optimal state. Finally, some reasonable and feasible suggestions are put forward for the obstacles that may be encountered in the implementation of the equity incentive plan.
【學(xué)位授予單位】：哈爾濱工業(yè)大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：F272.92;F721

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 肖淑芳;付威;;股權(quán)激勵(lì)能保留人才嗎?——基于再公告視角[J];北京理工大學(xué)學(xué)報(bào)(社會(huì)科學(xué)版);2016年01期

2 葉陳剛;劉桂春;洪峰;;股權(quán)激勵(lì)如何驅(qū)動(dòng)企業(yè)研發(fā)支出?——基于股權(quán)激勵(lì)異質(zhì)性的視角[J];審計(jì)與經(jīng)濟(jì)研究;2015年03期

3 王學(xué)龍;王復(fù)美;;審計(jì)機(jī)關(guān)績(jī)效評(píng)價(jià)指標(biāo)體系構(gòu)建——以審計(jì)署績(jī)效報(bào)告為例[J];審計(jì)研究;2015年01期

4 李春玲;任莉莉;;我國(guó)上市公司股權(quán)激勵(lì)實(shí)施效果的影響因素研究——基于股權(quán)激勵(lì)方案設(shè)計(jì)的視角[J];企業(yè)經(jīng)濟(jì);2014年09期

5 謝德仁;湯曉燕;;上市公司股權(quán)激勵(lì)計(jì)劃中的“10%/20%”現(xiàn)象探究[J];證券市場(chǎng)導(dǎo)報(bào);2014年05期

6 李小榮;張瑞君;;股權(quán)激勵(lì)影響風(fēng)險(xiǎn)承擔(dān):代理成本還是風(fēng)險(xiǎn)規(guī)避?[J];會(huì)計(jì)研究;2014年01期

7 肖淑芳;劉穎;劉洋;;股票期權(quán)實(shí)施中經(jīng)理人盈余管理行為研究——行權(quán)業(yè)績(jī)考核指標(biāo)設(shè)置角度[J];會(huì)計(jì)研究;2013年12期

8 朱焱;張孟昌;;企業(yè)管理團(tuán)隊(duì)人力資本、研發(fā)投入與企業(yè)績(jī)效的實(shí)證研究[J];會(huì)計(jì)研究;2013年11期

9 劉廣生;馬悅;;中國(guó)上市公司實(shí)施股權(quán)激勵(lì)的效果[J];中國(guó)軟科學(xué);2013年07期

10 肖星;陳嬋;;激勵(lì)水平、約束機(jī)制與上市公司股權(quán)激勵(lì)計(jì)劃[J];南開管理評(píng)論;2013年01期

相關(guān)碩士學(xué)位論文 前2條

1 肖云靜;股權(quán)激勵(lì)行權(quán)條件在我國(guó)房地產(chǎn)上市公司的研究[D];上海交通大學(xué);2014年

2 鄭吉慶;我國(guó)家電行業(yè)上市公司股權(quán)激勵(lì)效果評(píng)價(jià)[D];西南財(cái)經(jīng)大學(xué);2014年

，

本文編號(hào)：2117745